Psychiatry Investig.  2024 Mar;21(3):230-241. 10.30773/pi.2023.0253.

Exploratory Clinical Trial of a Depression Diagnostic Software That Integrates Stress Biomarkers and Composite Psychometrics

Affiliations
  • 1Research Institute of Minds.AI, Co. Ltd., Seoul, Republic of Korea
  • 2Institue of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
  • 3Department of Laboratory Medicine, Seoul Clinical Laboratories, Yongin, Republic of Korea
  • 4Department of Psychiatry, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea
  • 5Department of Psychiatry, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
  • 6Department of Communication, Yonsei University, Seoul, Republic of Korea
  • 7Hormone Analysis Center, Yonsei University College of Medicine, Seoul, Republic of Korea
  • 8Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Abstract


Objective
This study evaluated the clinical effectiveness of Minds.NAVI, a depression screening kit combining psychometric measures and stress hormone biomarkers, in a prospective clinical trial. The objective was to assess its potential as a depression screening tool and investigate the associations between psychological assessments, salivary hormone staging, and depression severity.
Methods
Thirty-five participants with major depressive disorder and 12 healthy controls (HCs) were included. The Minds.NAVI software, utilizing the PROtective and Vulnerable factors battEry Test (PROVE) and salivary cortisol/dehydroepiandrosterone (DHEA) analysis, was employed. The PROVE test is a comprehensive self-report questionnaire that assesses depressive symptoms, suicide risk, attachment style, adverse childhood experiences, mentalization capacity, and resilience. In addition, salivary cortisol and DHEA levels were measured to evaluate the functional stage of the hypothalamic–pituitary–adrenal (HPA) axis.
Results
Minds.NAVI exhibited 100% sensitivity, 91.7% specificity, and 97.9% accuracy in distinguishing depression from HCs within an exploratory small group. Salivary stress hormone phases showed changes with depression stage (p=0.030), and the proportion of patients with “adrenal exhaustion stage” was higher in the moderate/severe depression group (p=0.038). Protective/vulnerable factors differed significantly between controls and depressed groups (p<0.001). Cortisol awakening response inversely correlated with depressive symptom severity (r=-0.31, p=0.034).
Conclusion
This study suggested possible clinical effectiveness of Minds.NAVI, a depression screening tool that integrates psychometric measures and stress hormone biomarkers. The findings support the potential association between depression, chronic stress, and HPA axis hyporesponsiveness.

Keyword

Hypothalamic?pituitary?adrenal axis; Depression; Biomarker; Salivary hormone; Diagnosis; Cortisol
Full Text Links
  • PI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr